Diagnostic versus therapeutic doses of [177Lu-DOTA-Tyr 3]-octreotate: Uptake and dosimetry in somatostatin receptor-positive tumors and normal organs

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 151-159

  Müller, Cristina ^a   Forrer, Flavio ^a   Bernard, Bert F ^a   Melis, Marleen ^a   Konijnenberg, Mark ^b   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Mallinckrodt Medical BV   (Netherlands)

Author keywords

177Lu DOTA Tyr3 octreotate; Diagnosis; Peptide receptor; Radionuclide therapy; Somatostatin receptor; Specific activity

Indexed keywords

MONOCLONAL ANTIBODY KI 67; OCTREOTATE[3 TYROSINE DOTA] LU 177; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTORADIOGRAPHY; BLOOD; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG UPTAKE; EX VIVO STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY; LEWIS RAT; LIVER; MALE; MUSCLE; NONHUMAN; ORGAN; PANCREAS TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RAT; RECEPTOR DENSITY; TISSUE SECTION; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; AUTORADIOGRAPHY; HEALTH; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASMS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOMETRY; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN;

EID: 34247895618     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.309     Document Type: Conference Paper

References (30)

1. Reubi JC, Laissue J, Krenning E, et al. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates, and clinical implications. J Steroid Biochem Mol Biol 1992;43:27.
2. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analog SMS 201-995 in treatment of human endocrine tumors. J Clinl Invest 1994;93:1321.
3. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157.
4. 3]-octreotide-the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716.
5. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas-a prospective study. Ann Intern Med 1996;125:26.
6. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704.
7. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437.
8. 0]octreotide in patients. Eur J Nucl Med 2001;28:1319.
9. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32:133.
10. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S.
11. 90Y-DOTATOC. J Nucl Med 2002;43:610.
12. 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
13. 3]octreotate. J Clin Oncol 2004;22:2724.
14. 3]octreotide in patients with advanced. Semin Nucl Med 2006;36:147.
15. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439.
16. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847.
17. 111In-DOTATATE: Biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imag 2004;31:1257.
18. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imag 2004;31:1386.
19. Cremonesi M, Ferrari M, Bodei L, et al. Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 2006;47:1467.
20. 3]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Mol Imag 2006; Epub ahead of print.
21. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628.
22. 177Lu at high specific activities. Eur J Nucl Med Mol Imag 2003;30:917.
23. Bernard BF, Krenning E, Breeman WAP, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 2000;21:1079.
24. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000;182:311.
25. Zidan M, Pabst R. Lymphocyte proliferation in lymphoid organs of the dromedary camel using the monoclonal antibody MIB-5 against the proliferation-associated nuclear epitope Ki-67. Anat Histol Embryol 2002;31:286.
26. Stabin MG, Konijnenberg MW. Reevaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000;41:149.
27. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:67S.
28. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273.
29. Heppeler A, Froidevaux S, Macke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem-Eur J 1999;5:1974.
30. 3-octreotate in a small cell lung cancer animal model. Eur J Nucl Med Mol Imag 2006;33(Suppl. 2):S144.